Li T, Chen Z, Chen H
Department of Internal Medicine, First Affiliated Hospital.
Hua Xi Yi Ke Da Xue Xue Bao. 1992 Sep;23(3):339-42.
The hemorheologic properties are obviously abnormal in patients with cor pulmonale (CP), presenting as high hematocrit (HCT), hyperviscosity and hyper-viscoelasticity. Twenty patients suffering from CP with polycythemia were randomized into either an isovolemic hemodilution (IHD) group or control group. In the IHD group, 10 patients were treated by routine therapy combined with IHD. The other 10 patients in the control group were treated by routine therapy only. The results demonstrated that after treatment in IHD group, all viscoelasticity property parameters except eta p were decreased significantly. Oxygen delivery, oxygen transport capacity, and stroke volume and cardiac output were increased. Mean pulmonary artery pressure and total pulmonary resistance were decreased. However, in the control group only HCT and eta 0.512 were decreased after treatment. The viscosity and eta' of the whole blood in IHD group were decreased more markedly than those in the control group. IHD was well tolerated in most of the patients. There were no complications or side effects. Thus, IHD is a safe, effective and acceptable therapy, and it may play a role in the treatment of cor pulmonale.
肺心病（CP）患者的血液流变学特性明显异常，表现为高血细胞比容（HCT）、高粘度和高粘弹性。20例患有红细胞增多症的肺心病患者被随机分为等容血液稀释（IHD）组或对照组。在IHD组中，10例患者接受常规治疗联合IHD治疗。对照组的另外10例患者仅接受常规治疗。结果表明，IHD组治疗后，除ηp外的所有粘弹性特性参数均显著降低。氧输送、氧运输能力、每搏量和心输出量增加。平均肺动脉压和总肺阻力降低。然而，对照组治疗后仅HCT和η0.512降低。IHD组全血的粘度和η'比对照组降低更明显。大多数患者对IHD耐受性良好。无并发症或副作用。因此，IHD是一种安全、有效且可接受的治疗方法，可能在肺心病的治疗中发挥作用。
